610 related articles for article (PubMed ID: 37216792)
1. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
2. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
[TBL] [Abstract][Full Text] [Related]
4. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
5. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
[TBL] [Abstract][Full Text] [Related]
8. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
[TBL] [Abstract][Full Text] [Related]
9. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
[TBL] [Abstract][Full Text] [Related]
10. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
11. Robust spike-specific CD4
Federico L; Tvedt THA; Gainullin M; Osen JR; Chaban V; Lund KP; Tietze L; Tran TT; Lund-Johansen F; Kared H; Lind A; Vaage JT; Stratford R; Tennøe S; Malone B; Clancy T; Myhre AEL; Gedde-Dahl T; Munthe LA
Front Immunol; 2023; 14():1210899. PubMed ID: 37503339
[TBL] [Abstract][Full Text] [Related]
12. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
Wu X; Wang L; Shen L; He L; Tang K
J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
[TBL] [Abstract][Full Text] [Related]
13. Predominantly defective CD8
Taus E; Shino MY; Ibarrondo FJ; Hausner MA; Hofmann C; Yang OO
J Transl Med; 2023 Jun; 21(1):374. PubMed ID: 37291575
[TBL] [Abstract][Full Text] [Related]
14. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
[TBL] [Abstract][Full Text] [Related]
15. Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.
Leclerc M; Redjoul R; Le Bouter A; Beckerich F; Robin C; Parinet V; Pautas C; Menouche D; Bouledroua S; Roy L; Cabanne L; Nait-Sidenas Y; Fourati S; Maury S
J Hematol Oncol; 2022 Mar; 15(1):27. PubMed ID: 35303906
[TBL] [Abstract][Full Text] [Related]
16. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
[TBL] [Abstract][Full Text] [Related]
18. [COVID-19 vaccination for allogeneic hematopoietic stem cell recipients].
Nagafuji K
Rinsho Ketsueki; 2022; 63(9):1067-1077. PubMed ID: 36198531
[TBL] [Abstract][Full Text] [Related]
19. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.
Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
J Infect Chemother; 2023 Mar; 29(3):274-280. PubMed ID: 36442827
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]